TORECAN
LOE ApproachingNDAORALTABLET
Approved
Jul 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORECAN is an oral small-molecule tablet approved by Novartis in 1961 for an undisclosed indication. The specific mechanism of action and therapeutic class are not publicly documented in this dataset. The drug is currently approaching loss of exclusivity.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting reduced commercial team expansion and potential role consolidation before LOE.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TORECAN currently shows zero linked job openings, reflecting its mature, pre-LOE status. Working on this product is best suited for professionals managing established legacy products or preparing transition and lifecycle extension strategies.
Brand ManagerField Sales Representative
Worked on TORECAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.